Abstract
Diabetes is one of the largest therapeutic segments of global pharmaceutical
sales and during the last 10 years it has grown by a compound average growth
rate of nearly 20% from around US$4 billion in 1995 to over US$17 billion in
2005. Overall, anti-diabetic drugs sales are expected to grow dramatically
over the next five years to over US$22 billion in 2012 as the addressable
patient population continues to increase and new, oral, injectable and
pulmonary premium priced products enter the market to address high unmet
clinical needs.
The Global Diabetes Market assesses the markets for diabetes therapeutics, as
well as the markets for diagnostic products and those that treat diabetic
complications. This new report from Arrowhead Publishers incorporates new
clinical findings presented at the 2006 conference of the American Diabetes
Association into our product outlooks and financial forecasts. This report
also analyzes, clinically and financially, the leading products on the market,
the major players, as well as the groundbreaking new products in clinical
development. Financial forecasts are also provided for individual products as
well as for product classes.
| 
View Cart
